Application of ProTide technology to gemcitabine: a successful approach to overcome the key cancer resistance mechanisms leads to a new agent (NUC-1031) in clinical development.
about
Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspectiveNovel delivery approaches for cancer therapeutics.A G-quadruplex-binding compound showing anti-tumour activity in an in vivo model for pancreatic cancerNucleic Acid Bioconjugates in Cancer Detection and Therapy.Thiophene-expanded guanosine analogues of Gemcitabine.Improving nucleoside analogs via lipid conjugation: Is fatter any better?Nucleoside analogs and tuberculosis: new weapons against an old enemy.Pharmacological factors affecting accumulation of gemcitabine's active metabolite, gemcitabine triphosphate.ProTides of BVdU as potential anticancer agents upon efficient intracellular delivery of their activated metabolitesBifunctional aryloxyphosphoramidate prodrugs of 2'-C-Me-uridine: synthesis and anti-HCV activity.The ProTides Boom.Facile synthesis of the NNRTI microbicide MC-1220 and synthesis of its phosphoramidate prodrugs.Chemoselective N-deacetylation of protected nucleosides and nucleotides promoted by Schwartz's reagent.The protecting-group free selective 3'-functionalization of nucleosidesSynthetic Approaches for the Preparation of Phosphoramidate Prodrugs of 2'-Deoxypseudoisocytidine.Kinetin Riboside and Its ProTides Activate the Parkinson's Disease Associated PTEN-Induced Putative Kinase 1 (PINK1) Independent of Mitochondrial DepolarizationPancreatic Cancer Chemoresistance to Gemcitabine.Fluorinated nucleosides as an important class of anticancer and antiviral agents.Vitamin E Phosphate Nucleoside Prodrugs: A Platform for Intracellular Delivery of Monophosphorylated Nucleosides.Symmetrical diamidate prodrugs of nucleotide analogues for drug delivery.New [(η(5)-C5H5)Ru(N-N)(PPh3)][PF6] compounds: colon anticancer activity and GLUT-mediated cellular uptake of carbohydrate-appended complexes.Nucleobase and Nucleoside Analogues: Resistance and Re-Sensitisation at the Level of Pharmacokinetics, Pharmacodynamics and Metabolism
P2860
Q26752368-9BC4BF98-B677-45AB-B306-D0B55F5B5CAFQ30368171-29EE11AE-86AD-435F-B467-5D5CBB0D4C0DQ35745690-6E17F41E-BB48-410E-9670-1DE931D60E22Q35867875-18048F05-8D87-4C74-9524-5C4BE36A78D6Q36084790-CF54760C-0F8A-4EE8-9570-B90B54C93055Q36706248-99D6E595-9042-4D55-AC49-B55489AC6503Q38397331-D61242A0-58C2-43E0-B8A4-C8BF9775863EQ38673319-F9660233-40F2-4B3D-8879-4FB9805BE434Q38732666-678C6D8B-7D45-4FC7-824F-0F604BE87EE4Q40514370-EBBDCBE2-CFE7-48A5-B7F2-B23F00E1D00AQ40682239-8AB8640F-B57B-4A20-B11F-29A4358E900AQ41095817-2DFBEE04-D2EE-465C-85FA-ABBF4CD07E27Q41767606-9B16D0A5-B552-466B-BED3-A81A90DA1D78Q41952812-3AF9DF14-625D-4110-8B65-4B6A3EDFAF78Q42196760-B9158344-04C8-415A-9A76-B1038C7AB6CCQ42290109-D8979551-61B2-4591-9499-FA1900217212Q47135556-28BBC5F6-956D-4AB9-91F4-2FD32066DB10Q47637142-28588876-8A40-4A3D-8C63-93856901D0DFQ50132096-DD99CAE2-6C9B-4748-9AAA-ABC4FAEDD18EQ51000489-DC92F63F-A103-44FB-BF08-A6848EBE5CDFQ53095820-D068627D-3660-47F4-B40F-1E1935819FD9Q57175017-8B293AEC-C94E-411A-8417-705833A8A304
P2860
Application of ProTide technology to gemcitabine: a successful approach to overcome the key cancer resistance mechanisms leads to a new agent (NUC-1031) in clinical development.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Application of ProTide technol ...... 1031) in clinical development.
@en
Application of ProTide technol ...... echanisms leads to a new agent
@nl
type
label
Application of ProTide technol ...... 1031) in clinical development.
@en
Application of ProTide technol ...... echanisms leads to a new agent
@nl
prefLabel
Application of ProTide technol ...... 1031) in clinical development.
@en
Application of ProTide technol ...... echanisms leads to a new agent
@nl
P2093
P50
P356
P1476
Application of ProTide technol ...... -1031) in clinical development
@en
P2093
Emely Thompson
Jan Balzarini
Magdalena Slusarczyk
Malcolm Mason
Monica Huerta Lopez
Sarah Blagden
P304
P356
10.1021/JM401853A
P407
P577
2014-02-14T00:00:00Z